Benefits and Pitfalls of Plasmin Derivatives Application for Thrombolysis: A Narrative Review

Varování

Publikace nespadá pod Ústav výpočetní techniky, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

NIKITIN Dmitri MIKULÍK Robert TURANEK Jaroslav

Rok publikování 2024
Druh Článek v odborném periodiku
Časopis / Zdroj American Journal of Biomedical Science and Research
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://biomedgrid.com/pdf/AJBSR.MS.ID.003101.pdf
Doi http://dx.doi.org/10.34297/AJBSR.2024.23.003101
Klíčová slova Myocardial infarction; Ischemic stroke; Thrombosis; Thrombolysis; Thrombolytics; Plasmin(ogen); Alteplase; Liposome
Popis Cardio- and cerebrovascular thrombosis is a serious pathology with the highest lethality and disability rates in the world. The current thrombolytic therapy is mainly based on plasminogen activators, such as streptokinase, urokinase and tissue plasminogen activator. As soon as their target is ad hoc plasminogen activation, an addressed plasmin(ogen) delivery to a clot could have at least the same efficiency. Here we present in a form of narrative review thrombolytic potential of plasmin(ogen) and its derivatives, which in some experiments outperformed approved plasminogen activators. We believe that these factors will find their niches in clinical thrombolytic therapy in the near future.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info